Eli Lilly and Company ( NYSE: LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Lucas Montarce - CFO Mike Czapar - SVP, IR ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

In this article, we will take a look at the 12 Major Stocks to Buy According to Billionaires. The U.S. stock market had one of the worst starts, at least the worst start to a presidency since 1928.

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...